Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move

In a merger with troubled Angion Biomedica, Elicio Therapeutics has spied an opportunity to finally list on the Nasdaq as it prepares to push a cancer vaccine into phase 2 trials.